Xiangxue Pharmaceutical's low P/S ratio may be due to declining revenue and expectations of this trend continuing, potentially disappointing shareholders. Significant share price movement seems unlikely given current circumstances and recent revenue trends.

The company's share price fall is justified by its fundamental deterioration. It needs to return to revenue growth to regain investor enthusiasm. Last year's performance may indicate unresolved challenges, as it was worse than the annualised loss of 6% over the last half decade.

The company's declining income and under-performance compared to the industry's growth could account for the low P/S ratio. The current unimpressive P/S ratio reflects shareholders' beliefs in the company's dim future revenue potential.